首页 | 本学科首页   官方微博 | 高级检索  
     

宫颈小细胞神经内分泌癌的临床特点及治疗分析
引用本文:潘忠勉,石凤娟,李力. 宫颈小细胞神经内分泌癌的临床特点及治疗分析[J]. 国际妇产科学杂志, 2021, 48(4): 467-471. DOI: 10.12280/gjfckx.20200636
作者姓名:潘忠勉  石凤娟  李力
作者单位:530021 南宁,广西医科大学附属肿瘤医院妇瘤科暨区域性高发肿瘤早期防治研究教育部重点室验室
基金项目:广西科学研究与技术开发计划课题(桂科攻14124004)
摘    要:
目的:回顾性分析宫颈小细胞神经内分泌癌的临床资料,以期为该病的诊断、治疗提供依据.方法:收集广西医科大学附属肿瘤医院收治的59例宫颈小细胞神经内分泌癌患者的临床资料,并随访患者的预后情况.分别对患者的发病年龄、临床表现、人乳头瘤病毒(HPV)分型检测、病理诊断、不同临床分期的术后病理情况、治疗方案及生存情况进行统计分析...

关 键 词:宫颈肿瘤  宫颈小细胞神经内分泌癌  抗肿瘤联合化疗方案  诊断  治疗
收稿时间:2020-07-16

Clinical Features and Treatment Analysis of Small Cell Neuroendocrine Carcinoma of the Cervix
PAN Zhong-mian,SHI Feng-juan,LI Li. Clinical Features and Treatment Analysis of Small Cell Neuroendocrine Carcinoma of the Cervix[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 467-471. DOI: 10.12280/gjfckx.20200636
Authors:PAN Zhong-mian  SHI Feng-juan  LI Li
Affiliation:Department of Gynecologic Oncology, Guangxi Medical University Affiliated Tumor Hospital, Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning 530021, China
Abstract:
Objective: The clinical data of small cell neuroendocrine carcinoma of the cervix were analyzed retrospectively in order to provide the basis for the diagnosis and treatment of this disease. Methods: The clinical data of 59 patients with small cell neuroendocrine carcinoma of the cervix were collected in Guangxi Medical University Affiliated Tumor Hospital, and the prognosis of the patients was followed up. The age of onset, clinical manifestations, human papillomavirus (HPV) typing, pathological diagnosis, postoperative pathology in different clinical stages, treatment plan and survival were statistically analyzed. Results: The median age of onset of the 59 patients was 43.6 years. The main clinical manifestation is irregular vaginal bleeding (53 cases, 89.8%). The positive rate of HPV18 in HPV typing was the highest (48 cases, 81.4%). Immunohistochemical tests showed that 58 cases (98.3%) were positive for Syn, 49 cases (83.1%) were positive for CgA, 58 cases (98.3%) were positive for NSE, and 50 cases (84.7%) were positive for CD56. Thirty-nine patients with clinical stage ⅠB and ⅡA underwent surgical treatment, including 23 patients (59.0%) with deep muscular infiltration, 11 patients (28.2%) with lymph vascular space infiltration (LVSI), and 9 patients (23.1%) with pelvic lymph node metastasis. The cut-off date for follow-up was July 31, 2019. All patients were followed for more than 5 years. Of the 59 patients, 19 survived and 40 died. The mean survival time was 22.6 months, and the median survival time was 20.2 months. Kaplan-Meier Log-Rank test was used for survival analysis. Clinical stage (Log-Rank P=0.000), lymph node metastasis (Log-Rank P=0.015), and depth of tumor invasion (Log-Rank P=0.009) were the prognostic factors. LVSI (Log-Rank P=0.450), neoadjuvant chemotherapy (Log-Rank P=0.856), postoperative adjuvant radiotherapy (Log-Rank P=0.900), TP/TC (paclitaxel or docetaxel + platinum) regimen or EP (etoposide+ cisplatin) regimen (Log-Rank P=0.939) had no significant effect on prognosis. Conclusions: The main clinical manifestation of this disease is irregular vaginal bleeding. The disease is closely related to HPV18 infection. Infiltration and metastasis occurred in early cases. Diagnosis of the disease requires immunohistochemistry. The later the clinical stage, with lymph node metastasis and deep tumor infiltration, the worse the prognosis. Early diagnosis and treatment are the key to improve the curative effect.
Keywords:Uterine cervical neoplasms  Small cell neuroendocrine carcinoma of the cervix  Antineoplastic combined chemotherapy protocols  Diagnosis  Therapy  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《国际妇产科学杂志》浏览原始摘要信息
点击此处可从《国际妇产科学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号